PL1756310T3 - Sposób wykrywania polimorfizmów w genie ABCB1 związanych z brakiem odpowiedzi na lek działający na OUN oraz lek zawierający inhibitor ABCB1 do stosowania w leczeniu chorób związanych z OUN - Google Patents

Sposób wykrywania polimorfizmów w genie ABCB1 związanych z brakiem odpowiedzi na lek działający na OUN oraz lek zawierający inhibitor ABCB1 do stosowania w leczeniu chorób związanych z OUN

Info

Publication number
PL1756310T3
PL1756310T3 PL05748517T PL05748517T PL1756310T3 PL 1756310 T3 PL1756310 T3 PL 1756310T3 PL 05748517 T PL05748517 T PL 05748517T PL 05748517 T PL05748517 T PL 05748517T PL 1756310 T3 PL1756310 T3 PL 1756310T3
Authority
PL
Poland
Prior art keywords
cns
medicament
abcb1
lack
response
Prior art date
Application number
PL05748517T
Other languages
English (en)
Inventor
Manfred Uhr
Florian Holsboer
Elisabeth Binder
Bertram Müller-Myhsok
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of PL1756310T3 publication Critical patent/PL1756310T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05748517T 2004-05-12 2005-05-12 Sposób wykrywania polimorfizmów w genie ABCB1 związanych z brakiem odpowiedzi na lek działający na OUN oraz lek zawierający inhibitor ABCB1 do stosowania w leczeniu chorób związanych z OUN PL1756310T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57008504P 2004-05-12 2004-05-12
EP05748517A EP1756310B1 (en) 2004-05-12 2005-05-12 Method for detecting polymorphisms in the ABCB1 gene associated with a lack of response to a CNS-active medicament and medicament comprising an ABCB1 inhibitor for use in the treatment of CNS related diseases.
PCT/EP2005/005194 WO2005108605A2 (en) 2004-05-12 2005-05-12 Polymorphisms in abcb1 associated with a lack of clinical response to medicaments

Publications (1)

Publication Number Publication Date
PL1756310T3 true PL1756310T3 (pl) 2013-05-31

Family

ID=34979627

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05748517T PL1756310T3 (pl) 2004-05-12 2005-05-12 Sposób wykrywania polimorfizmów w genie ABCB1 związanych z brakiem odpowiedzi na lek działający na OUN oraz lek zawierający inhibitor ABCB1 do stosowania w leczeniu chorób związanych z OUN

Country Status (6)

Country Link
US (1) US8030033B2 (pl)
EP (1) EP1756310B1 (pl)
DK (1) DK1756310T3 (pl)
ES (1) ES2397345T3 (pl)
PL (1) PL1756310T3 (pl)
WO (1) WO2005108605A2 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008976A1 (en) 2006-07-14 2008-01-17 The Govt. Of The Usa As Represented By The Secretary Of The Department Of Health And Human Services Abcbi genotyping to predict microtubule-stabilizing-agent-induced toxicity
PL2158331T3 (pl) 2007-06-12 2013-01-31 Max Planck Gesellschaft Nowe polimorfizmy ABCB1 związane z brakiem odpowiedzi klinicznej na leki
US20140024539A1 (en) * 2011-02-02 2014-01-23 Translational Genomics Research Institute Biomarkers and methods of use thereof
CN108929913A (zh) * 2018-08-21 2018-12-04 潍坊德诺泰克生物科技有限公司 用于检测rs2032582的引物探针组及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2697207A1 (en) 1999-07-30 2001-02-08 Epidauros Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications
US7034036B2 (en) * 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20050069936A1 (en) * 2003-09-26 2005-03-31 Cornelius Diamond Diagnostic markers of depression treatment and methods of use thereof

Also Published As

Publication number Publication date
US8030033B2 (en) 2011-10-04
WO2005108605A3 (en) 2006-01-12
EP1756310A2 (en) 2007-02-28
EP1756310B1 (en) 2012-12-05
DK1756310T3 (da) 2013-03-18
WO2005108605A2 (en) 2005-11-17
US20080064609A1 (en) 2008-03-13
ES2397345T3 (es) 2013-03-06

Similar Documents

Publication Publication Date Title
ZA200703714B (en) 5-heteroaryl thiazoles and their use as P13K inhibitors
EP1651251A4 (en) METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
EP1752536A4 (en) POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
ZA200704668B (en) An austenitic steel and steel product
IL180759A0 (en) Indazoles useful in treating cardiovascular diseases
TWI368272B (en) Cleaning liquid and cleaning method
IL180872A0 (en) Substituted 8-aminoalkylthio-xanthines, and the use thereof as inhibitors of the dipeptidyl peptidase iv
GB0704021D0 (en) Computer hypnosis therapy device and method
EP1933880A4 (en) OLIGORIBONUCLEOTIDES AND METHODS OF USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES
IL185554A0 (en) Method of prognosis of mental diseases, e.g. sutism and cerebral palsy
EP1774029A4 (en) METHOD FOR DETECTING THE RISKS OF NON-INSULIN-DEPENDENT DIABETES AND FOR TREATING THIS TYPE OF DIABETES
IL179747A0 (en) Novel indazole carboxamides and their use
GB0504890D0 (en) Process management system and produciton management system
GB2416542B (en) Fuel product and process
IL183931A0 (en) Method for detecting mental disorders and pharmaceutical compositions for treating them
PT2026821E (pt) Misturas binárias de ácido hialurónico e uso terapêutico das mesmas
EP2097378A4 (en) NOVEL INHIBITORS OF SEH AND USE THEREOF
PL1740298T3 (pl) Sposób granulacji złoża zawiesinowego
AU2003241400A8 (en) Amyotrophic lateral sclerosis treatment with cyclooxygenase-2 inhibitors
GB0402629D0 (en) Reactor and process
EP1963521A4 (en) THERAPEUTIC USE FOR THE INHIBITOR OF ALPHA 1 PROTEINASE IN HEMATOPOIESE
GB0411145D0 (en) Protease inhibitors and their therapeutic applications
TW200833336A (en) Method of treatment of obesity
DK1756310T3 (da) Fremgangsmåde til at påvise polymorfi i ABCB1-genet associeret med mangel af respons for et CNS-aktivt lægemiddel samt lægemiddel omfattende en ABCB1-inhibitor til anvendelse i behandlingen af CNS-relaterede sygdomme
TWI340092B (en) Liquid discharge method and liquid discharge head